Dihydroartemisinin inhibits mtorc1 signaling by activating the ampk pathway in rhabdomyosarcoma tumor cells

Medicine and Dentistry

• Mammalian Target of Rapamycin 100%
• Dihydroartemisinin 80%
• Protein Kinase 40%
• Reduced Nicotinamide Adenine Dinucleotide Dehydrogenase (Ubiquinone) 40%
• Rhabdomyosarcoma 26%
• Mechanistic Target of Rapamycin 20%
• Cells 20%
• Tumor Cell 13%
• Artesunate 13%
• Therapeutic Procedure 13%
• Receptor 6%
• Protein 6%
• Mammalian Target of Rapamycin Complex 1 6%
• Tensin 6%
• Xenograft 6%
• Cell Proliferation 6%
• Phosphotransferase 6%
• Tumor Progression 6%
• Antineoplastic Activity 6%
• Cell Viability 6%
• Ectopic Expression 6%
• Prodrug 6%
• Phosphatidylinositide 6%
• Growth 6%
• Fk 506 Binding Protein 6%
• Rhabdomyosarcoma Cell 6%

Pharmacology, Toxicology and Pharmaceutical Science

• Dihydroartemisinin 80%
• Protein Kinase 40%
• Reduced Nicotinamide Adenine Dinucleotide Dehydrogenase (Ubiquinone) 40%
• Rhabdomyosarcoma 26%
• Mammalian Target of Rapamycin 20%
• Artesunate 13%
• Receptor 6%
• Protein 6%
• Phosphotransferase 6%
• Tumor Growth 6%
• Phosphatidylinositide 6%
• Fk 506 Binding Protein 6%
• Antimalarial Agent 6%
• Phosphatase 6%
• Mammalian Target of Rapamycin Complex 1 6%
• Tensin 6%

Biochemistry, Genetics and Molecular Biology

• Protein Kinase 40%
• Growth 13%
• Binding Protein 6%
• Tensin 6%
• Mammalian Target of Rapamycin Complex 1 6%
• Phosphoinositides 6%
• Cell Proliferation 6%
• Ectopic Expression 6%
• Electric Potential 6%
• Dissociation 6%
• Phosphatase 6%
• Kinase 6%
• Antineoplastic Activity 6%
• Cell Viability 6%
• Protein 6%